IRON furnishes Q3 2025 results press release and corporate update

Rhea-AI Filing Summary

Disc Medicine, Inc. (IRON) furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025, and providing a corporate update. The details are contained in a press release furnished as Exhibit 99.1.

The information under Item 2.02 is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act, and it is not incorporated by reference into other filings unless expressly stated. The company’s common stock trades on the Nasdaq Global Market under the symbol IRON.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001816736false00018167362025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2025

DISC MEDICINE, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39438	85-1612845
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
321 Arsenal Street Suite 101
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 674-9274

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		IRON		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Disc Medicine, Inc. announced its financial results for the third quarter ended September 30, 2025 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item 2.02 of this Current Report on Form 8-K shall be deemed to be furnished and not filed:

Exhibit No.		Description
99.1		Press release issued by Disc Medicine, Inc. on November 6, 2025, furnished herewith.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			DISC MEDICINE, INC.
Date:	November 6, 2025	By:	/s/ John Quisel, J.D., Ph.D.
			Name: John Quisel, J.D., Ph.D. Title: Chief Executive Officer

FAQ

What did Disc Medicine (IRON) announce in this 8-K?

The company announced financial results for the quarter ended September 30, 2025, and provided a corporate update.

Which period does the update cover for IRON?

It covers the third quarter ended September 30, 2025.

Where can I find the detailed results for Disc Medicine?

Details are in the press release furnished as Exhibit 99.1.

Is the information in this 8-K furnished or filed?

The information under Item 2.02 is furnished and not deemed filed under Section 18 of the Exchange Act.

Is the 8-K information incorporated by reference into other filings?

It is not incorporated by reference unless expressly set forth by specific reference.

What is Disc Medicine’s trading symbol and exchange?

The common stock trades under IRON on the Nasdaq Global Market.

What exhibits accompany this 8-K?

Exhibit 99.1 (press release dated November 6, 2025) and Exhibit 104 (Cover Page Interactive Data File).